Literature DB >> 1585636

Generation of reassortants between African arenaviruses.

I S Lukashevich1.   

Abstract

Lassa (LAS) and Mopeia (MOP) viruses are African arenaviruses which are carried by wild rodents and occasionally transferred to humans. In humans and nonhuman primates, Lassa causes mortality in 60% of untreated cases, whereas Mopeia does not cause mortality and has been known to protect monkeys from lethal challenge with Lassa. These two African arenaviruses also differ in their lethality for suckling outbred mice and in their plaque sizes under agar overlay. MOP virus induces small plaques and lethal infection after intracerebral (ic) inoculation. In contrast, LAS inoculation does not kill mice and the virus induces large plaques. After coinfection of Vero cells with LAS and MOP viruses some phenotypic reassortants which produced small plaques and were not lethal for outbred mice were isolated and plaque-purified. Dot-blot hybridization using LAS and MOP cDNA probes specific for L and S RNA segments revealed a genotype consisting of the L RNA of MOP and the S RNA of LAS (MOP/LAS reassortant). Adoptive transfer experiments demonstrated an ability of immune splenocytes from CBA mice intraperitoneally infected with the MOP/LAS reassortants to protect recipient mice against lethal disease after ic inoculation with LAS virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585636     DOI: 10.1016/0042-6822(92)90514-p

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.

Authors:  Kristian G Andersen; B Jesse Shapiro; Christian B Matranga; Rachel Sealfon; Aaron E Lin; Lina M Moses; Onikepe A Folarin; Augustine Goba; Ikponmwonsa Odia; Philomena E Ehiane; Mambu Momoh; Eleina M England; Sarah Winnicki; Luis M Branco; Stephen K Gire; Eric Phelan; Ridhi Tariyal; Ryan Tewhey; Omowunmi Omoniwa; Mohammed Fullah; Richard Fonnie; Mbalu Fonnie; Lansana Kanneh; Simbirie Jalloh; Michael Gbakie; Sidiki Saffa; Kandeh Karbo; Adrianne D Gladden; James Qu; Matthew Stremlau; Mahan Nekoui; Hilary K Finucane; Shervin Tabrizi; Joseph J Vitti; Bruce Birren; Michael Fitzgerald; Caryn McCowan; Andrea Ireland; Aaron M Berlin; James Bochicchio; Barbara Tazon-Vega; Niall J Lennon; Elizabeth M Ryan; Zach Bjornson; Danny A Milner; Amanda K Lukens; Nisha Broodie; Megan Rowland; Megan Heinrich; Marjan Akdag; John S Schieffelin; Danielle Levy; Henry Akpan; Daniel G Bausch; Kathleen Rubins; Joseph B McCormick; Eric S Lander; Stephan Günther; Lisa Hensley; Sylvanus Okogbenin; Stephen F Schaffner; Peter O Okokhere; S Humarr Khan; Donald S Grant; George O Akpede; Danny A Asogun; Andreas Gnirke; Joshua Z Levin; Christian T Happi; Robert F Garry; Pardis C Sabeti
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

2.  Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses.

Authors:  Dmitry A Moshkoff; Maria S Salvato; Igor S Lukashevich
Journal:  Virus Genes       Date:  2006-12-02       Impact factor: 2.332

3.  Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro.

Authors:  Melissa W Hayes; Ricardo Carrion; Jerritt Nunneley; Andrei E Medvedev; Maria S Salvato; Igor S Lukashevich
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

5.  Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Authors:  Juan C Zapata; Marco Goicochea; Yuka Nadai; Lindsay M Eyzaguirre; Jean K Carr; Luke J Tallon; Lisa Sadzewicz; Garry Myers; Claire M Fraser; Qi Su; Mahmoud Djavani; Igor S Lukashevich; Maria S Salvato
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

6.  Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system.

Authors:  Minjie Chen; Shuiyun Lan; Rong Ou; Graeme E Price; Hong Jiang; Juan Carlos de la Torre; Demetrius Moskophidis
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

7.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 8.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

9.  LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.

Authors:  I S Lukashevich; J D Rodas; I I Tikhonov; J C Zapata; Y Yang; M Djavani; M S Salvato
Journal:  Arch Virol       Date:  2004-08-30       Impact factor: 2.574

10.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.